Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition. Those BMI requirements for Wegovy are set by the MHRA in the medicine's licence and confirmed by NICE's appraisal of semaglutide for weight management (TA875). Because Wegovy is a prescription-only medicine, meeting a BMI threshold is the starting point, not the finish line — a GPhC-registered prescriber reviews your full health picture before any prescription is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Imagine you've just typed your height and weight into the NHS BMI calculator and you're looking at a figure of, say, 28.5. Your first question is usually: does that mean I qualify for Wegovy? The answer is: possibly, but it depends on what sits alongside that number.
Under Wegovy's MHRA licence, there are two routes in. The first is straightforward: a BMI of 30 or above meets the wegovy bmi requirement on its own. The second applies if your BMI sits between 27 and 29.9, at that level, you also need at least one weight-related condition. Conditions that count include type 2 diabetes, raised blood pressure, dyslipidaemia (high cholesterol or triglycerides), obstructive sleep apnoea and cardiovascular disease. Prediabetes and osteoarthritis are also commonly considered, though the prescriber makes the final call.
One practical note on the ethnic-background adjustment: UK clinical guidance recommends using BMI thresholds 2.5 kg/m² lower for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. That means the 30 threshold becomes effectively 27.5, and the 27 threshold becomes 24.5 with a qualifying condition. This isn't automatic, your prescriber applies it during assessment.
A BMI above either threshold still doesn't mean a prescription follows automatically. Contraindications (a personal or family history of medullary thyroid carcinoma, for instance, or certain pancreatic conditions) can rule it out entirely. BMI is the entry criterion, not the whole assessment.
Many people arrive at a private clinic after discovering the NHS route is harder to access than they expected. That frustration is understandable. NICE's recommendation under TA875 is narrower than the product licence: for NHS prescribing, the guideline requires a BMI of at least 35 alongside at least one weight-related comorbidity, and the medicine must be used within a specialist weight management service. The 27–29.9 route that exists in the licence does not translate into a typical NHS pathway under TA875.
There's also a two-year maximum under NICE's NHS guidance, something that doesn't apply to private prescriptions, which are assessed on an ongoing clinical basis. Waiting lists for specialist services can run to many months.
For people whose BMI sits in the 27–34.9 range, or who simply don't want to wait, a private prescription through a regulated online pharmacy is often the practical route. If you want to understand how Wegovy fits into the wider cost of private weight-loss treatment, that context is worth reading before you start. If you're weighing up whether you're likely to be eligible, it helps to read through what are the requirements for wegovy as they apply to private prescribing, since the threshold is lower than the NHS route but the clinical review is just as thorough.
Scotland, Wales and Northern Ireland set their own access criteria for NHS prescribing, which can differ from NHS England's. If you're based outside England and considering the NHS route, your GP or specialist can explain the devolved guidance that applies to you.
A consultation for Wegovy (whether private or NHS-referred) will involve more than quoting your BMI. Expect questions about your weight history, relevant diagnoses, current medicines, and any previous attempts at structured weight management. Photo ID and live weight verification are part of how regulated private services confirm the numbers you've provided.
The weight requirements for Wegovy don't change once you're on treatment, but your prescriber will review your response at regular intervals. NICE's guidance notes that if you've lost less than five percent of your starting body weight after six months at your highest tolerated dose, continuing treatment should be reconsidered. That review happens at every repeat, not just at the start.
Storage is worth mentioning briefly: Wegovy pens are kept in the fridge, and many people settle them on the fridge door shelf, easy to see, easy to remember, away from anything that might freeze them. For the precise temperature window and what to do if a pen has been left out, the Wegovy temperature requirements page covers that in full.
If you're comparing Wegovy's thresholds with those of other licensed weight-loss medicines, the page covering what bmi is required for wegovy is worth reading alongside the BMI requirements for semaglutide treatments broadly. The licensed thresholds are similar across the GLP-1 class, but the clinical profiles of the medicines differ. Our clinical team at nume can walk you through which option fits your situation.
If you'd like a prescriber to assess whether you meet the requirements for Wegovy, speak to our prescribers through a free consultation, reviewed the same day by a real clinician, not software.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.